Subsequent Events	12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events On January 22, 2024, the Company issued 81,086 shares of common stock to an investor as payment of accrued interest on notes payable. On March 23, 2024, the Company signed a Distribution Agreement with AHAR Pharma Limited, relating to the distribution of products in West Africa. This agreement supersedes all earlier negotiations and verbal and written understandings between the parties. The Company originally executed a Distribution Agreement with AHAR Pharma in 2013. This agreement was modified in 2016 and 2018 to include both Biostax and Cytocom, Inc. Cytocom, Inc. defaulted on the agreement and the Company was unable to settle with AHAR until a settlement was reached with Cytocom, Inc.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//855/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483399/855-10-50-2

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration